$GENTING (3182.MY)$
taurx delay the answer to MHRA,hopefully they will submit in March and the approval from NICE come before June
taurx delay the answer to MHRA,hopefully they will submit in March and the approval from NICE come before June
5
$SUNZEN (0148.MY)$
once the dispose of animal division completed,the only direction is north
once the dispose of animal division completed,the only direction is north
1
$SUNZEN-WC (SUNZEN GROUP BHD) (0148WC.MY)$
take out the loss from animal devision,PAT will be 3m
take out the loss from animal devision,PAT will be 3m
1
$SUNZEN (0148.MY)$
next Quarter profits surely crazy,2.25m + 3m =5m++
forwards ,no more loss from animal division,more capital to make profits,4 m /quarter will lift share price to 0.6 atleast
next Quarter profits surely crazy,2.25m + 3m =5m++
forwards ,no more loss from animal division,more capital to make profits,4 m /quarter will lift share price to 0.6 atleast

2
$DRBHCOM (1619.MY)$
Perodua's technology in EV obviously cannot lower costs, Proton is very likely to defeat Perodua to become the first in Malaysia.
Perodua's technology in EV obviously cannot lower costs, Proton is very likely to defeat Perodua to become the first in Malaysia.
Translated

冷水16
commented on
1
2
$BJFOOD (5196.MY)$
break down trend,flying mode
break down trend,flying mode
2
$GENTING (3182.MY)$
forming head & shoulder bottom?
forming head & shoulder bottom?
1
1
$GENTING (3182.MY)$
Excluding other factors, assuming TauRx submits its data as scheduled in February, the stock price may experience a small uptick. By the end of March, if the MHRA approval is granted, the stock price could rise to a range of 4.4–4.8. If NICE grants approval in April, the stock price may break through the long-term resistance at 5.2.
If any of these three milestones encounters issues, the downside risk appears limited. Given that the potential benefits of TauRx are not yet ful...
Excluding other factors, assuming TauRx submits its data as scheduled in February, the stock price may experience a small uptick. By the end of March, if the MHRA approval is granted, the stock price could rise to a range of 4.4–4.8. If NICE grants approval in April, the stock price may break through the long-term resistance at 5.2.
If any of these three milestones encounters issues, the downside risk appears limited. Given that the potential benefits of TauRx are not yet ful...
3
1